News

NVIDIA's Unstoppable Growth: A Promising Future Ahead

NVIDIA's Unstoppable Growth: A Promising Future Ahead

Data Center Expansion Drives Unprecedented Scale

NVIDIA (NASDAQ: NVDA) is making waves in the technology sector, showcasing a significant performance surge recently. The company reported an impressive revenue of $57 billion, marking a 62.5% year-over-year increase and demonstrating its strongest quarterly growth to date. Data center revenues played a significant role, soaring to $51.2 billion, with an incredible year-over-year growth of 66.5% and a quarter-over-quarter increase of 24.6%. This remarkable performance reflects the growing demand and deployment of their surpassing Blackwell GB300 GPUs and innovative NVLink networking technologies.

The gaming division showed steady revenue at $4.27 billion, representing a healthy 30% year-over-year increase. Additionally, the professional visualization segment rose significantly, recording $760 million in revenue, while the automotive sector grew 31.8% year-over-year with $592 million in sales. OEM and other segments reported consistent figures at $174 million. Interestingly, the company's GAAP gross margin exhibited a slight dip to 73.4%, a minor reduction attributable to increased costs in high-bandwidth memory and packaging complexities. In stark contrast, the net margin upheld a robust figure of around 56%, which allowed NVIDIA to generate over $22 billion in free cash flow, including $12.5 billion in share repurchase activities for the quarter.

Management expressed strong confidence, highlighting over $500 billion in combined orders for the Blackwell and upcoming Rubin GPUs, extending well into 2026. This indicates an unprecedented level of visibility across various sectors, including hyperscalers and enterprise AI programs. Notably, the B300 model accounts for two-thirds of Blackwell's sales, which has notably replaced the previous Hopper architecture in leading cloud data centers. The anticipated Rubin platform, scheduled for release in the latter half of 2026, is projected to enhance performance capabilities by about double that of Blackwell, solidifying NVIDIA’s competitive edge.

Such orders align with forecasts indicating significant global growth in AI data-center capacity, expected to grow from 49 GW in 2024 to 141 GW by 2030. This growth trend points to a prolonged infrastructure expansion rather than a temporary spike. Major players like Microsoft, Amazon, and Alphabet currently possess AI-buildout backlogs exceeding $600 billion, creating a sustained demand for NVIDIA GPUs far beyond the year 2026.

However, sales to China reached only $50 million in the last quarter, dramatically diminishing from 23% of total revenue a year prior to just 5%. This shift reflects the impact of U.S. export restrictions and directives from Beijing that compel hyperscalers to use local suppliers such as Huawei. Despite this, NVIDIA's guidance for the upcoming quarter suggests a revenue forecast of $65 billion, signifying ongoing growth momentum independent of Chinese markets.

Some reports suggest that Washington is reassessing the export clearance for NVIDIA's H200 GPUs, potentially enhancing performance of existing models and unlocking an additional $17 billion sales opportunity annually. The ongoing discussions indicate a dedicated effort from NVIDIA to engage with both U.S. and Chinese governments to secure balanced trade access.

NVIDIA's CEO, Jensen Huang, rebutted concerns about an 'AI bubble', emphasizing that monetization in AI is now decisively accelerating. For instance, Meta’s recent GEM foundation model improvements have significantly boosted ad conversions on platforms like Instagram and Facebook, demonstrating tangible AI-driven returns on investment.

Although investor concerns about cross-financing between hyperscalers and AI start-ups exist, Huang affirmed that different sectors and nations would independently fund their AI infrastructures. NVIDIA's robust balance sheet, devoid of circular capital risks, supports its strategic positioning.

Driven by heightened expectations, analysts have uplifted NVIDIA's EBITDA forecasts, now estimating a growth of 9.4% in 2025, progressing to 24.8% in 2027, and a remarkable 28.9% by 2028. This translates into a robust annualized growth rate of 45% compared to the previously reported 33%. In parallel, free cash flow estimates have surged by 12.2%, projecting cumulative totals surpassing $150 billion through 2028, even amid substantial R&D and share buyback initiatives. Analysts predict that EBITDA margins would stabilize around 65% as free cash flow conversion enhances with reduced capital expenditures in relation to revenue streams.

NVIDIA’s market capitalization stands impressively at $4.35 trillion, with a forward P/E ratio of 38.2 and a PEG ratio of 0.74, reflecting a manageable short interest of 0.98%. The company's balance sheet also showcases a net-cash position with minimal debt, ensuring flexibility for continued share buybacks and investments.

Interestingly, inventory days have increased to 130, highlighting a proactive strategy in stockpiling essential materials ahead of the anticipated launch of the Rubin GPU. Commitments for supply have surged by 63% on a quarter-over-quarter basis, evidencing strategic risk management in the face of high-bandwidth memory and other bottlenecks. Despite these proactive measures, working-capital absorption has successfully maintained liquidity, with management projecting a positive cash flow each quarter.

Beyond its traditional markets, NVIDIA is forging new partnerships, like the recent collaboration with Palantir Technologies (NASDAQ: PLTR), aiming to integrate NVIDIA's CUDA-X stack within Palantir’s AIP platform to bolster enterprise-level AI capabilities. This partnership is designed to hasten inference workloads using the Blackwell architecture and cement NVIDIA’s presence in government and defense sectors.

Meanwhile, new legislation in Congress, such as the proposed GAIN AI Act, could prioritize U.S. computing capabilities domestically. If successful, this bill would limit the sale of H-series GPUs internationally until domestic supply meets demand, enhancing NVIDIA’s national footprint and backlog while fostering an expected $50 billion in funding towards AI infrastructure from the U.S. government.

Treasury Secretary Scott Bessent hinted at possible exceptions that may permit the export of legacy Blackwell units into China once Rubin becomes the American strategic standard, providing further opportunity to remain ahead in innovation despite export controls.

NVIDIA currently trades at a forward P/E of 38, slightly below AMD's 56 but offers better earnings growth. Similarly, on a forward price-to-sales multiple of 23.4, NVDA appears undervalued against its five-year average of 26.6. Support levels are identified at $179.80 and $169.03 (100- and 200-day EMAs), with potential downside risk if broader macro conditions permit.

Resistance levels peak at $195 to $200, a point where past rallies have stalled. A robust performance exceeding $205 could trigger significant purchasing momentum, potentially directing shares toward a target of $241, reflecting a projected 35% upside.

For Q4 FY26, NVIDIA forecasts revenues of approximately $65 billion, translating to 17% sequential growth, indicating persistent internal demand strength, while gross margins are expected around 74.8%. Management anticipates another wave of product launches targeting autonomous systems and enterprise AI servers early in 2026, further broadening their market reach beyond GPUs into full-stack AI infrastructure.

With backlog figures surpassing $1 trillion in the hyperscaler sector, and government investments in AI rising, NVIDIA’s forward-looking earnings visibility stands unparalleled in the mega-cap technology landscape.

Resilient against market fluctuations, following a recent rebound to $182.37, NVDA maintains position within the $173 to $195 range, showcasing normalized momentum indicators and levels of investor confidence. Support areas have seen significant accumulation, and should overall market sentiment stabilize, institutional investors could propel shares upward toward the $200 to $205 target in Q1 2026.

Strategic Assessment

Even under conservative estimates—considering no revenue from China, a gross margin stabilization at 73%, and gradual CapEx increment—NVIDIA finds itself well positioned for an EBITDA compound annual growth rate exceeding 45% from 2025 to 2028 accompanied by impressive free-cash flow advancements. The indications across AI cycles—characterized by backlogs from hyperscalers and enterprise adoption—point convincingly toward a sustained demand outlook.

Verdict: Strong Buy

Taking into account the enduring growth potential, unmatched profitability metrics, and clear order forecast visibility, NVIDIA is classified as a Strong Buy. With a fair value prognosis of $240 to $260, and a bullish scenario potentially reaching $404 by 2026, the stock currently exemplifies a discount compared to its historical growth multiple. The AI sector development is still in its nascent stages, and robust liquidity safeguards the company during volatility.

Frequently Asked Questions

What drove NVIDIA's recent financial performance?

NVIDIA's recent performance was significantly driven by increased demand for data-center solutions, particularly from AI hyperscalers, coupled with robust growth in both gaming and enterprise visualization revenues.

How does NVIDIA's partnership with Palantir enhance its offerings?

The partnership with Palantir enables NVIDIA to integrate its advanced AI technologies into enterprise applications, facilitating faster inference workloads and embedding their solutions in critical sectors like defense.

What are the implications of export restrictions for NVIDIA?

Export restrictions have limited NVIDIA's market share in China, but the company remains positioned for strong growth in other regions, with significant revenue projections in domestic markets.

How does the GAIN AI Act affect NVIDIA's sales strategy?

If enacted, the GAIN AI Act will fortify NVIDIA's domestic sales by prioritizing U.S. compute capacity, potentially diverting short-term sales elsewhere but enhancing overall backlogs in the U.S.

What are the growth projections for NVIDIA over the next few years?

Analysts forecast high growth for NVIDIA, anticipating substantial EBITDA growth rates upwards of 45% through 2028, paired with increasing free cash flow despite investments in research and development.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Ensign Lawsuit Brews: Investor Stakes High by Dec. 7

Updated Category News Views 40

Ensign's Alleged Missteps Uncovered Man, grabbing headlines in the finance world often feels like catching a whirlwind, and yet, here we are with Ensign Group's latest debacle. This isn't some run-of-the-mill story we're sifting through. It's a class action lawsuit with teeth, aiming to rope in investors who played ball during a hefty stretch running from February 10,...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 273

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 240

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 167

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 0

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Master Sommeliers and Italian Producers Clash on Wine Lists

Updated Category News Views 121

Wines Jockeying for New York’s Coveted Lists Alright, picture a stage set up in New York City like an arena. But instead of gladiators, you've got master sommeliers on one side and Italian wine producers on the other, each armed with their own arguments. They're locked in a battle over what it really takes to get a bottle imbedded on a New York City's prestigious wine...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 120

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 184

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Duolingo Faces Class Action: Deadline Looms for Plaintiffs

Updated Category News Views 208

Shaking up the education sector like a hot potato, investors have been thrown for a loop with Duolingo’s latest legal debacle. News broke that Kahn Swick & Foti, LLC, with significant backing from their heavyweight partner and former Louisiana Attorney General Charles C. Foti Jr., is spearheading a class action lawsuit against Duolingo, Inc. (NasdaqGS: DUOL). It’s one...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 135

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading

Top 5 Most Recently Viewed Articles

MAAS Embraces Healthcare with Strategic Carve Group Acquisition

Updated Category News Views 117

MAAS Expands into Healthcare and Wellness Maase Inc. (NASDAQ: MAAS) recently announced a significant expansion into the healthcare and wellness sector following its acquisition of Carve Group Ltd. This strategic move signifies MAAS's commitment to innovate within the traditional wellness product landscape by integrating advanced biotechnology. The acquisition is more than...

Continue Reading
Metavesco Welcomes ADHC's Strategic Purchase of OTCfi Tokens

Updated Category News Views 117

Metavesco Celebrates Collaboration with ADHC In a significant development, Metavesco, Inc. (NASDAQ: MVCO) recently expressed excitement over American Diversified Holdings Corporation (NASDAQ: ADHC) announcing their Digital Asset Treasury (DAT) purchase of OTCfi tokens. This partnership is seen as a positive move towards enhancing the visibility and growth of the...

Continue Reading
Understanding Short Interest Trends in Discover Financial

Updated Category News Views 188

Understanding Short Interest Trends in Discover Financial Discover Financial's stock ticker, DFS, has recently experienced an increase in its short interest, rising to 10.94% since the last report. The total number of shares sold short now stands at 3.11 million, equating to 1.42% of the available shares for trading. If we consider the current trading volume, it would...

Continue Reading
Immunic Reaches Key Milestone in Multiple Sclerosis Trials

Updated Category News Views 201

Immunic Completes Enrollment in Phase 3 Trials Immunic, Inc. (NASDAQ: IMUX), a pioneering biotechnology firm, recently reached a significant milestone by completing enrollment for its Phase 3 ENSURE trials, which focus on its lead drug, vidofludimus calcium. These trials target patients living with relapsing multiple sclerosis (RMS) and aim to evaluate the drug's...

Continue Reading
Ergonomic Apparel Revolution: Elevating Back Health in Daily Life

Updated Category News Views 86

Rising Trend of Ergonomic Posture Wear The growing trend of ergonomic apparel highlights the importance of posture-related health concerns. As people spend more time seated and engaged with screens, discomfort is becoming increasingly common. A recent review has brought attention to this phenomenon, shedding light on how ergonomic clothing can play a pivotal role in...

Continue Reading